Ligand id: 4754

Name: empagliflozin

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: empagliflozin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 4
Rotatable bonds 6
Topological polar surface area 108.61
Molecular weight 450.14
XLogP 2.9
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

1. Abdul-Ghani MA, DeFronzo RA. (2008)
Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.
Endocr Pract, 14 (6): 782-90. [PMID:18996802]
2. Bays H. (2009)
From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus.
Curr Med Res Opin, 25 (3): 671-81. [PMID:19232040]
3. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P. (2012)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
Diabetes Obes Metab, 14 (1): 83-90. [PMID:21985634]
4. Nair S, Wilding JP. (2010)
Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.
J. Clin. Endocrinol. Metab., 95 (1): 34-42. [PMID:19892839]
5. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ et al.. (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
N. Engl. J. Med., 373 (22): 2117-28. [PMID:26378978]